From Wall Street to Capitol Hill
At the press conference at Pfizer headquarters on Manhattan's East 42nd Street, Kindler hammered home two messages: Pfizer
would remain No. 1 and this megamerger would not repeat past mistakes. "We have learned a lot from prior transactions. We
are very mindful of the importance of protecting [Wyeth's R&D expertise]." And: "This is not about a single product. It is
about creating a broad, diversified portfolio of businesses....And it is just such a perfect fit."
News of the deal—the third largest in pharma history—got immediate reviews from Wall Street all the way to Capitol Hill.
The headlines tell the tale: "Not What the Doctor Ordered" in the Washington Post. "Pfizer: Try, Try Again" in the Hartford Courant. "Wyeth's Deal Big, But Pfizer Still Needs a Blockbuster" on
http://TheStreet.com/. "Did Pfizer Just Commit Suicide?" on
http://MotleyFool.com/. "Is Jeffrey Kindler Brave or Crazy?" on the Harvard Business School Web site.
Not all were nasty. Analysts who had long promoted a major merger as Pfizer's only option—the firm had more than $27 billion
in cash on its balance sheet at year's end—grudgingly approved. "Pfizer is in the most desperate state of anyone in the industry
in terms of patent expirations," says Standard & Poor's analyst Herman Saftlas. "We feel that it is in the best interests
of Pfizer to do a deal like this in order to shore up the top line."
Investors voiced their enthusiasm for the deal by sending the company's stock down 10 percent.
The next day, at a hastily called investor lunch at the St. Regis, Kindler tried again. "This is not a case of simply taking
one, big monolithic company...and then putting another one on top of that," he said. "We will be the leader in just about
every single market in which we compete."
The deal played into the intense politics of the economic crisis. The fact that Pfizer was able to raise $22.5 billion from
five banks was quickly mistaken as a sign that frozen credit markets were beginning to thaw. Four of the banks had received
tax-payer money in the form of TARP funds, so Kindler's announcement that 19,500 employees, or 15 percent of the combined
company, would lose their jobs by 2013 stoked populist anger. During its grilling of eight national bank heads in early February,
the House Financial Services Committee found the Pfizer deal a convenient example of bailout abuse. Meantime, the Greenlining
Institute, a Berkeley, Calif., advocacy group, petitioned Treasury Secretary Timothy Geithner to block the transaction unless
Pfizer and Wyeth lower drug prices.
The first major merger to come before the new Obama administration, the deal is attracting other controversy as well. The
combined company would be the nation's fourth largest by market value ($162 billion), after Exxon, Wal-Mart, and Procter &
Gamble. While the merger poses no apparent antitrust threat, the American Antitrust Institute has asked Attorney General Eric
Holder for a "careful and skeptical investigation," arguing that there is "scant reason" to believe the merger would improve
R&D, and good cause to think it would make Pfizer's bureaucratic situation worse while enriching company managers and bankers.
The letter concludes, "That the merger of Pfizer with Wyeth will benefit consumers is far from a foregone conclusion."
At least the price is right. All companies are selling at prices lower than usual, and Wyeth is no exception, says Chuck Farkas,
head of healthcare for Bain & Company. "The 30 percent premium is below where Wyeth traded in '06 and '07," he says. Pfizer
plans to bankroll the deal with $22.5 billion in cash, $22.5 billion in debt, and $23 billion in stock. To help pay for it,
Pfizer's quarterly dividend of 7 percent will be cut in half, a move that has already sparked shareholder venom. "Many are
likely to sell, but that might be a good thing," says Peter Young, president of Young & Partners. "Pfizer would prefer to
have new stockholders who invest because they have faith in the new company."
At the moment, such faith requires a willing suspension of disbelief in pharma megamergers.